| pubmed-article:1839742 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1839742 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:1839742 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1839742 | lifeskim:mentions | umls-concept:C0145106 | lld:lifeskim |
| pubmed-article:1839742 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:1839742 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1839742 | pubmed:dateCreated | 1992-5-28 | lld:pubmed |
| pubmed-article:1839742 | pubmed:abstractText | Teicoplanin, a new glycopeptide antibiotic similar to vancomycin, was evaluated in treating 36 hospitalized patients suffering from various Gram-positive infections. The 36 patients received teicoplanin once daily as a mean intravenous injection of 550 mg/day (range 200-800 mg/day). Previous antimicrobial therapy was used in 28% of patients. The mean duration of therapy was 7.5 days (range 3-38 days). The overall clinical success rate was 94%. 24/36 patients (66%) had positive microbiology. Elimination of the pathogens was seen in 75% of all evaluable cases. Four patients with early prosthetic valve endocarditis due to coagulase negative Staphylococcus (3 patients) and Propionibacterium acnes (1 patient) had a favorable clinical and microbiological outcome. No adverse drug reactions were observed. Teicoplanin is safe and effective in the therapy of many different infections caused by Gram-positive bacteria. | lld:pubmed |
| pubmed-article:1839742 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1839742 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1839742 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1839742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1839742 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1839742 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1839742 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1839742 | pubmed:issn | 1120-009X | lld:pubmed |
| pubmed-article:1839742 | pubmed:author | pubmed-author:ReidT MTM | lld:pubmed |
| pubmed-article:1839742 | pubmed:author | pubmed-author:SmithC CCC | lld:pubmed |
| pubmed-article:1839742 | pubmed:author | pubmed-author:DouglasJ GJG | lld:pubmed |
| pubmed-article:1839742 | pubmed:author | pubmed-author:NathwaniDD | lld:pubmed |
| pubmed-article:1839742 | pubmed:author | pubmed-author:GouldI MIM | lld:pubmed |
| pubmed-article:1839742 | pubmed:author | pubmed-author:GolderDD | lld:pubmed |
| pubmed-article:1839742 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1839742 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:1839742 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1839742 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1839742 | pubmed:pagination | 315-20 | lld:pubmed |
| pubmed-article:1839742 | pubmed:dateRevised | 2009-8-4 | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:meshHeading | pubmed-meshheading:1839742-... | lld:pubmed |
| pubmed-article:1839742 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1839742 | pubmed:articleTitle | An open study of teicoplanin in the treatment of gram-positive infections. | lld:pubmed |
| pubmed-article:1839742 | pubmed:affiliation | Infection Unit, City Hospital, Aberdeen, Scotland UK. | lld:pubmed |
| pubmed-article:1839742 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1839742 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1839742 | lld:pubmed |
